Agoracom Blog Home

Posts Tagged ‘biopharma’

« Older Entries

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Posted by Brittany McNabb at 11:10 AM on Wednesday, April 16th, 2025

From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.

A Biopharma Platform Tackling Today’s Toughest Health Challenges

Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.

The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.

Lucid-MS: Targeting the Root Cause of Multiple Sclerosis

At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.

Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.

What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.

unbuzzd™: A Consumer Wellness Product with Scientific Backing

In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.

Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.

Multiple Value Streams, One Vision

Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.

With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.

A Biotech Story Worth Watching

With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.

It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.


YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , , , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Posted by Brittany McNabb at 1:18 PM on Monday, March 24th, 2025

Key Takeaway for Investors:
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 clinical trial for Lucid-21-302 (Lucid-MS), an experimental drug for multiple sclerosis (MS). The drug was found to be safe and well-tolerated, paving the way for the next phase of clinical testing.

What Happened?
The company conducted a Phase 1 trial to test the safety of Lucid-MS in healthy volunteers. The study followed strict protocols, including a final review by a Safety Review Committee, which confirmed there were no safety concerns or serious side effects.

Why This Matters:
Lucid-MS is a first-of-its-kind drug designed to protect the myelin sheath around nerve fibers, which is damaged in MS patients. Unlike existing MS treatments, which primarily focus on the immune system, Lucid-MS directly works to stabilize myelin, potentially slowing disease progression.

Next Steps:
With safety confirmed, Quantum BioPharma now plans to move forward with a Phase 2 trial, which will test Lucid-MS in MS patients to evaluate its effectiveness in treating the disease.

CEO Statement:
Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the significance of this milestone, stating that the company is now closer to making a breakthrough treatment for MS patients a reality.

Investor Outlook:
The successful completion of Phase 1 is a major step toward potential drug approval and commercialization. Investors should keep an eye on upcoming Phase 2 trial developments, as positive results could significantly increase the drug’s market potential.

What Does Lucid-21-302 Do? (In Simple Terms)

Lucid-21-302 (Lucid-MS) is a new experimental drug designed to protect nerve fibers in people with multiple sclerosis (MS).

How Does It Work?
Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. In MS, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

Why Is This Important?
By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.
If future trials confirm its effectiveness, it could be a game-changer for people living with MS.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086

 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Quantum BioPharma Targets $40B MS Market with Lucid-MS Following Successful Phase 1 Trial – Poised for $1B+ Potential

Posted by Brittany McNabb at 4:32 PM on Thursday, February 27th, 2025

Industry Outlook and Quantum BioPharma’s Trajectory

The multiple sclerosis (MS) treatment market is undergoing a transformation. With increasing research into neuroprotection and remyelination, the industry is shifting beyond traditional immune-modulating therapies. The global MS drug market, expected to surpass $40 billion by 2030, is being driven by demand for innovative treatments that go beyond symptom management.

Quantum BioPharma Ltd. (NASDAQ: QNTM) is emerging as a key player in this landscape with its lead drug candidate, Lucid-21-302 (Lucid-MS). The successful completion of its Phase 1 multiple ascending dose clinical trial represents a significant step toward offering MS patients a potential first-in-class neuroprotective treatment. The trial results confirmed no safety concerns and set the stage for Phase 2 trials in MS patients, positioning Quantum BioPharma as an industry leader in advancing non-immunomodulatory solutions.

Voices of Authority

Scientific leaders continue to emphasize the need for alternative MS treatments that address demyelination, rather than focusing solely on immune suppression. Quantum BioPharma’s Vice-President of Scientific and Clinical Affairs, Dr. Andrzej Chruscinski, reinforced the importance of Lucid-MS in meeting this demand:

“We are thrilled that Lucid-MS was deemed safe and well-tolerated in healthy participants. This marks an important milestone and allows for the next steps in the clinical development of Lucid-MS.”

Quantum BioPharma’s CEO, Zeeshan Saeed, highlighted the company’s broader vision:

“By completing this trial and demonstrating safety in healthy participants, we are now closer to initiating a Phase 2 trial of Lucid-MS in people with MS. We look forward to executing our milestones, driven by our mission to arrest demyelination in MS.”

Quantum BioPharma’s FLASH Highlights

Quantum BioPharma has strategically positioned itself at the forefront of neurodegenerative and metabolic disorder treatment development, with a pipeline designed to address high-value, underserved markets. Key achievements include:

  • Lucid-MS Progression: Completion of a successful Phase 1 trial, clearing a major regulatory hurdle and setting up Phase 2 studies.
  • Unbuzzd™ Market Expansion: Quantum BioPharma holds a 25.71% equity stake in Celly Nutrition Corp., licensing its breakthrough alcohol detox beverage, unbuzzd™, with royalty payments contributing to sustained revenue streams.
  • Innovative Growth Strategy: The company continues to diversify its treasury, with forward-thinking financing strategies including cryptocurrency investments and dual listings on Upstream, expanding global investor accessibility.

Real-world Relevance

For MS patients, treatment breakthroughs can mean the difference between maintaining mobility and facing long-term disability. Lucid-MS aims to fill a critical treatment gap by focusing on stabilizing and protecting the myelin sheath, addressing the core issue of MS progression rather than just reducing flare-ups.

Similarly, unbuzzd™ is tackling a widely recognized consumer need—accelerating alcohol metabolism while promoting recovery. With growing attention on functional beverages and wellness products, the supplement represents an additional revenue channel backed by scientifically validated results.

Looking Ahead with Quantum BioPharma

With Lucid-MS advancing to Phase 2 trials and continued market expansion of unbuzzd™, Quantum BioPharma remains well-positioned for long-term growth and industry leadership. The company’s dual focus on biotech innovation and strategic investment diversification sets it apart as a high-potential opportunity for investors seeking exposure to both pharmaceutical breakthroughs and high-growth consumer health markets.

Conclusion

Quantum BioPharma is aligning itself with the industry’s shift toward next-generation MS treatments and functional wellness solutions. The successful completion of its Phase 1 trial for Lucid-MS, combined with its diversified portfolio and strategic financial initiatives, reinforces its role as a compelling player in biotech and healthcare innovation. As the company moves forward with its Phase 2 trial and market expansion plans, investors will be watching closely for its next milestones.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086

 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Targets $40B MS Market with Lucid-MS Following Successful Phase 1 Trial – Poised for $1B+ Potential

Quantum BioPharma (Formerly FSD Pharma) Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Posted by Brittany McNabb at 5:21 PM on Tuesday, November 19th, 2024

In a bold move to safeguard its interests and fight back against market manipulation, Quantum BioPharma (Formerly FSD Pharma)has filed a $700 million lawsuit against CIBC, RBC & Others. The lawsuit alleges that the banks engaged in the controversial practice of “spoofing,” which involves manipulating stock prices by placing fake buy and sell orders to create a false illusion of market demand or supply. According to Quantum BioPharma, this tactic has been used to artificially depress its stock price, potentially causing substantial harm to its investors and undermining the company’s growth prospects.

The Allegations: A Market Manipulation Scheme

Zeeshan Saeed, CEO of Quantum BioPharma, discussed the shock of discovering that the company’s stock had been targeted by a manipulation scheme. He explained that spoofing, a practice where orders are placed and canceled in fractions of a second, can have a profound impact on market prices. These orders are meant to deceive other investors into believing that there is either a shortage of supply or an excess of demand, thus influencing market behavior without any intention to execute the orders. While the practice can be difficult to track due to the speed and subtlety of the actions involved, its effects on stock prices can be devastating.

The suit alleges that CIBC, RBC & others used this technique to artificially suppress Quantum BioPharma’s stock price, potentially wiping out substantial investor value. The company claims that this market manipulation has not only impacted its share price but has also hindered its ability to raise capital, secure financing, and pursue its growth strategies.

A Systemic Issue Impacting Micro-Cap Companies

The conversation extended to the broader implications of stock manipulation, particularly for micro-cap and nano-cap companies that are especially vulnerable to such tactics. Jason Sawyer, Head of Finance and M&A, pointed out that small companies with lower market capitalization and liquidity are often the targets of these manipulations. These tactics are detrimental not only to individual companies but to the entire market ecosystem, particularly in Canada’s venture capital sector. Sawyer emphasized that the loss of trust in the integrity of financial markets—especially within the micro-cap space—has had far-reaching consequences, making it increasingly difficult for companies like Quantum BioPharma to attract investment.

Both Saeed and Sawyer underscored that this lawsuit is not only important for Quantum BioPharma but for many other companies in the sector that may have been victims of similar manipulation. The legal action seeks to address a systemic issue that has been undermining the growth of innovative companies and damaging the confidence of retail investors.

A Legal Strategy with Significant Implications

Quantum BioPharma’s lawsuit, filed in the Southern District of New York, is a strategic step to ensure that the company’s interests are protected and that justice is served. The Southern District is renowned for its experience in handling complex financial cases, making it a favorable jurisdiction for cases of this nature.

The law firm representing Quantum BioPharma is taking the case on a contingency basis, signaling confidence in the strength of the lawsuit. This mirrors past successful cases, such as Erin Brockovich’s legal efforts, and suggests that the firm believes the case has merit without requiring upfront payment. Shareholders of Quantum BioPharma have expressed strong support for the lawsuit, recognizing its potential to restore fairness and the natural order to supply and demand in the company’s market activity, while compensating the company for the immense damage caused.

Additionally, the company is providing a platform for investors who believe they have been harmed by the alleged manipulation, offering them the opportunity to join the legal action and submit claims. This has fostered a sense of unity among shareholders and further strengthens the company’s resolve in its legal battle.

Potential Industry-Wide Impact

This lawsuit has the potential to set a significant precedent for other companies affected by similar forms of market manipulation. Quantum BioPharma has already received inquiries from other firms seeking guidance on how to pursue similar legal actions, highlighting the broader relevance of the case.

While the lawsuit is expected to take time, with motions to dismiss likely to be filed by the banks, the company remains focused on its core business activities. The litigation is seen as a crucial step in protecting the company’s long-term interests and ensuring that its shareholders are treated fairly in the marketplace. Discovery, the phase in which both parties exchange evidence, is expected to begin after motions are resolved, which could take 9 to 15 months.

Commitment to Shareholders and Future Growth

Quantum BioPharma has made it clear that its primary focus remains the ongoing commercialization of its innovative biotech products, including its neuroprotective compound, Lucid-MS. However, the company views the legal action as a secondary but essential part of its strategy to secure a fair and transparent market environment. A successful outcome in the lawsuit could not only recover damages for the company but also provide significant financial support for continued research and development, as well as potential acquisitions.

Furthermore, Quantum BioPharma’s leadership has reaffirmed its commitment to its shareholders. The company’s actions, including the filing of this lawsuit and its ongoing efforts to protect investor value, demonstrate its determination to safeguard the interests of its investors and ensure that the company can continue to thrive despite the challenges it faces.

Conclusion: Fighting for Market Integrity

Quantum BioPharma’s lawsuit is a bold stand against market manipulation and an important step in the broader fight for fairness and transparency in financial markets. By taking legal action against two of Canada’s largest banks, the company is not only seeking justice for itself and its investors but is also sending a message that such manipulative practices will not be tolerated.

As the legal battle unfolds, Quantum BioPharma remains committed to its mission of advancing groundbreaking biotech solutions while ensuring that its shareholders can invest in a company that values integrity, transparency, and accountability. The outcome of this case could have far-reaching implications for the biotech sector, offering a crucial opportunity to restore trust in the venture capital markets and set a positive precedent for other companies facing similar challenges.

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, FSD Pharma Inc., Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma (Formerly FSD Pharma) Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Quantum BioPharma Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Posted by Brittany McNabb at 3:18 PM on Monday, November 18th, 2024

Quantum BioPharma (Formerly FSD Pharma) has filed a groundbreaking $700 million lawsuit against major Canadian banks, CIBC and RBC, alleging a scheme of stock price manipulation known as “spoofing.” CEO and Co-Chairman Zeeshan Saeed explains that this isn’t just a shot in the dark—industry experts estimate that damages could exceed $1 billion for $QNTM. 

The company’s legal team, confident in the strength of the case, has agreed to take it on a contingency basis, signaling their belief that this could be a watershed moment for both Quantum BioPharma and the entire small cap sector.

“Our goal is to seek justice for our shareholders and stop manipulative practices that hurt ordinary investors,” Saeed stated, underscoring the severity of the issue.

SPOOFING: A MARKET MANIPULATION TACTIC WITH HIGH STAKES

The crux of the lawsuit revolves around a deceptive trading tactic known as spoofing, where large orders are placed and then canceled to manipulate stock prices. According to Zeeshan, this method has been used by CIBC and other financial institutions to artificially drive down Quantum BioPharma’s share price, resulting in significant losses. This isn’t an isolated issue—similar market manipulation has been flagged by advocacy groups like Save Canadian Mining.

The case has been filed in the U.S. District Court for the Southern District of New York, a jurisdiction known for its expertise in financial offenses. Zeeshan emphasized the importance of this venue, noting that “the judges understand the nuances of these complex financial crimes.”

FIGHTING FOR SHAREHOLDERS

Beyond the financial toll, the impact on shareholder confidence has been severe. Zeeshan spoke candidly about the personal toll this manipulation has taken, including threats to his safety. Yet, he remains steadfast in his commitment to Quantum BioPharma’s future, outlining a strategy that could see the company investing in its pipeline and potentially issuing dividends to shareholders if the lawsuit is successful.

George and Zeeshan both drew comparisons to landmark legal battles like the Erin Brockovich case, illustrating how a small player can take on corporate giants and make a real difference.

If you enjoy David vs Goliath stories, watch or listen to this interview to see how this could transform Quantum BioPharma’s future and potentially end market manipulation in the small cap sector once and for all.

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Posted by AGORACOM-JC at 6:36 PM on Thursday, February 11th, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.  

Nowhere is this more important than in the world of disruptive technologies, biotech and pharma.  Each of these industries share two distinct traits:

  • The possibility for explosive growth with disruptive new products
  • Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.  

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.    

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.  

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

Tags: , , , , , , ,
Posted in AGORACOM Beyond The Expert, All Recent Posts, Featured, Mountain Valley MD, Valeo Pharma Inc, Xphyto Therapeutics | Comments Off on VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

Innocan Pharma $INNO.ca Announces Successful Production of #CBD Loaded Liposomes under Aseptic Conditions $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:57 AM on Friday, January 22nd, 2021
Innocan-Blog
  • Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
  • This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

Herzliya, Israel and Calgary, Alberta–(January 22, 2021) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.

This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.

The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.

Read More: https://agoracom.com/ir/InnocanPharma/forums/discussion/topics/753657-innocan-pharma-announces-successful-production-of-cbd-loaded-liposomes-under-aseptic-conditions/messages/2299445#message

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca Announces Successful Production of #CBD Loaded Liposomes under Aseptic Conditions $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 5:51 PM on Wednesday, November 4th, 2020
Innocan-Blog
  • InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
  • The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
  • From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research

By: Liz Scherer

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).

There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).

Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.

Why CBD and Why Now?

CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.

CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.

The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.

Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.

Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Could #Cannabis Eliminate The High-Cost And High-Stakes Of Current #Psoriasis Medicines? SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 6:04 PM on Thursday, October 29th, 2020

SPONSOR: Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. In addition, the company filed an international patent application for a novel cannabis-based psoriasis treatment. This patent application makes claim of a topical pharmaceutical composition used to treat the symptoms of itching and inflammation associated with psoriasis.

  • “The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027.
Innocan-Blog

Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?

  • Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol.
  • The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 
  • A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis.
  • Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

By: Kate-Madonna Hindes

The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well. 

Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore. 

A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.

Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.

Image Credit: Aleksandr_Kravtsov | Getty Images via The Fresh Toast

Can CBD alone help psoriasis? 

Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.” 

A 2016 study published in the journal Current Clinical Pharmacology found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.  

While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.

Source: https://www.greenentrepreneur.com/article/358275

Tags: , , , , , , , , ,
Posted in All Recent Posts, Innocan Pharma Corporation | Comments Off on Could #Cannabis Eliminate The High-Cost And High-Stakes Of Current #Psoriasis Medicines? SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

« Older Entries